Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary of BGI Group (SHE: 300676), based in China. The collaboration aims to localize and transform comprehensive cancer care by introducing automation platforms for sequencing pipelines across the entire cycle of precise diagnosis and treatment of cancer. The partnership will also focus on the registration and application of cancer early screening and companion diagnostic products.
Focus on Precision Diagnosis and Treatment
The partnership will leverage Berry Genomics’ HIFI technology system, which has already completed a large-scale prospective cohort study for early liver cancer screening, positioning the company as an industry leader. Berry Genomics’ product portfolio is extensive, covering tumor genetic susceptibility testing, early screening, companion diagnostics, efficacy evaluation, and prognosis monitoring. The company has served over 900 hospitals and hundreds of thousands of cancer patients, making this partnership a significant step in enhancing cancer diagnostics and treatment.
MGI Tech’s Global Reach and Expertise
MGI Tech, founded in 2016, has a business presence in more than 80 countries worldwide. The company’s expertise in automation platforms for sequencing pipelines will be instrumental in the partnership’s goal to improve cancer diagnostics and early screening. By combining Berry Genomics’ HIFI technology and product portfolio with MGI Tech’s global reach and automation capabilities, the partnership aims to revolutionize the precision medicine landscape for cancer.
Implications for Cancer Care
This strategic partnership between Berry Genomics and MGI Tech is set to transform the localization and automation of cancer diagnostics and early screening. The collaboration will not only enhance the efficiency and accuracy of cancer treatment but also expand access to advanced diagnostic tools and services globally.-Fineline Info & Tech
